Circio Holding ASA – Key events and financial highlights – 2H 2025 and YTD 2026

Summary by AI BETAClose X

Circio Holding ASA announced preliminary financial highlights and key events for the second half of 2025 and year-to-date 2026, reporting a net cash balance of NOK 42 million as of March 31, 2026, following a rights issue in Q1 2026 that raised approximately NOK 68.6 million gross. The company highlighted significant advancements in its circVec technology, demonstrating up to 40-fold enhanced AAV expression in heart tissue and a 50-fold enhancement in eye tissue, and has entered a feasibility study with a major pharmaceutical corporation. New research collaborations were also established, and an abstract was selected for presentation at the ASGCT annual meeting.

Disclaimer*

UK 100

Latest directors dealings